156 related articles for article (PubMed ID: 8129747)
1. Effects of anandamide on cannabinoid receptors in rat brain membranes.
Childers SR; Sexton T; Roy MB
Biochem Pharmacol; 1994 Feb; 47(4):711-5. PubMed ID: 8129747
[TBL] [Abstract][Full Text] [Related]
2. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
Mackie K; Devane WA; Hille B
Mol Pharmacol; 1993 Sep; 44(3):498-503. PubMed ID: 8371711
[TBL] [Abstract][Full Text] [Related]
3. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
Vogel Z; Barg J; Levy R; Saya D; Heldman E; Mechoulam R
J Neurochem; 1993 Jul; 61(1):352-5. PubMed ID: 8515284
[TBL] [Abstract][Full Text] [Related]
4. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Devane WA; Hanus L; Breuer A; Pertwee RG; Stevenson LA; Griffin G; Gibson D; Mandelbaum A; Etinger A; Mechoulam R
Science; 1992 Dec; 258(5090):1946-9. PubMed ID: 1470919
[TBL] [Abstract][Full Text] [Related]
5. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.
Deutsch DG; Chin SA
Biochem Pharmacol; 1993 Sep; 46(5):791-6. PubMed ID: 8373432
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
Deutsch DG; Lin S; Hill WA; Morse KL; Salehani D; Arreaza G; Omeir RL; Makriyannis A
Biochem Biophys Res Commun; 1997 Feb; 231(1):217-21. PubMed ID: 9070252
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments.
Yousif MH; Oriowo MA
Pharmacol Res; 1999 Nov; 40(5):415-21. PubMed ID: 10527656
[TBL] [Abstract][Full Text] [Related]
9. Binding of aminoalkylindoles to noncannabinoid binding sites in NG108-15 cells.
Stark S; Pacheco MA; Childers SR
Cell Mol Neurobiol; 1997 Oct; 17(5):483-93. PubMed ID: 9353590
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Ross RA; Gibson TM; Brockie HC; Leslie M; Pashmi G; Craib SJ; Di Marzo V; Pertwee RG
Br J Pharmacol; 2001 Feb; 132(3):631-40. PubMed ID: 11159715
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
Breivogel CS; Griffin G; Di Marzo V; Martin BR
Mol Pharmacol; 2001 Jul; 60(1):155-63. PubMed ID: 11408610
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374).
Gifford AN; Bruneus M; Lin S; Goutopoulos A; Makriyannis A; Volkow ND; Gatley SJ
Eur J Pharmacol; 1999 Oct; 383(1):9-14. PubMed ID: 10556675
[TBL] [Abstract][Full Text] [Related]
13. Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes.
Pacheco MA; Ward SJ; Childers SR
J Neurochem; 1994 May; 62(5):1773-82. PubMed ID: 8158127
[TBL] [Abstract][Full Text] [Related]
14. New dawn of cannabinoid pharmacology.
Devane WA
Trends Pharmacol Sci; 1994 Feb; 15(2):40-1. PubMed ID: 8165721
[No Abstract] [Full Text] [Related]
15. Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain.
Nicholson RA; Liao C; Zheng J; David LS; Coyne L; Errington AC; Singh G; Lees G
Brain Res; 2003 Jul; 978(1-2):194-204. PubMed ID: 12834914
[TBL] [Abstract][Full Text] [Related]
16. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes.
Sagan S; Venance L; Torrens Y; Cordier J; Glowinski J; Giaume C
Eur J Neurosci; 1999 Feb; 11(2):691-9. PubMed ID: 10051770
[TBL] [Abstract][Full Text] [Related]
17. Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices.
Ameri A; Wilhelm A; Simmet T
Br J Pharmacol; 1999 Apr; 126(8):1831-9. PubMed ID: 10372827
[TBL] [Abstract][Full Text] [Related]
18. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
19. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide.
Hillard CJ; Edgemond WS; Campbell WB
J Neurochem; 1995 Feb; 64(2):677-83. PubMed ID: 7830060
[TBL] [Abstract][Full Text] [Related]
20. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors.
Edgemond WS; Campbell WB; Hillard CJ
Prostaglandins Leukot Essent Fatty Acids; 1995; 52(2-3):83-6. PubMed ID: 7784462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
